Effects of botulinum toxin A on patient‐specific keloid fibroblasts in vitro

Haubner, Frank; Leyh, Michaela; Ohmann, Elisabeth; Sadick, Haneen; Gassner, Holger G.

doi:10.1002/lary.24456

Cited by 34 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the literature, concentrations between 1 and 10 IU/mL were used 11,24–26 ; according to the package inserts, a dose of 5 IU per injection for overactive bladder, 1.25 to 2.5 units per injection for blepharospasm or strabismus (Botox), 27 and 4 IU per intramuscular injection (Botox Cosmetic, Allergan Inc., Irvine, Calif.) 28 are recommended. Furthermore, medical use generally involves significantly higher doses than cosmetic treatment.…”

Section: Discussionmentioning

confidence: 99%

Botulinum Toxin A: Dose-dependent Effect on Reepithelialization and Angiogenesis

Gugerell

Schmid

Buchberger

et al. 2016

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Background:Botulinum (neuro)toxin A (BoNT) is widely used in the field of plastic and reconstructive surgery. Among treatment of pain, hyperhidrosis, or aesthetic purposes, it is also used to enhance wound healing and prevent excessive scar formation. Some clinical data already exist, but only little is known on a cellular level. The aim of this study was to evaluate the effect of BoNT on cells essential for wound healing in vitro. Therefore, primary human keratinocytes and endothelial cells were treated with different concentrations of BoNT and tested on proliferation, migration, and angiogenic behavior.Methods:BoNT was exposed to human keratinocytes and endothelial cells in a low (1 IU/mL), medium (10 IU/mL), and high (20 IU/mL) concentrations in cell culture. Proliferation and migration of the 2 cell types were observed and also the angiogenic potential of endothelial cells in vitro.Results:BoNT 20 IU/mL negatively influenced proliferation and migration of keratinocytes but not those of endothelial cells. Angiogenesis in vitro was less effective with the highest BoNT concentrations tested. Low concentrations of BoNT supported sprouting of endothelial cells.Conclusions:High concentrations of botulinum toxin interfered with wound closure as keratinocytes’ proliferation and migration were deteriorated. Furthermore, BoNT concentrations of 20 IU/mL constrain in vitro vessel formation but do not influence proliferation or migration of endothelial cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Botulinum Toxin A: Dose-dependent Effect on Reepithelialization and Angiogenesis

Gugerell

Schmid

Buchberger

et al. 2016

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

show abstract

“…Haubner et al [70] recently tested patient-specific keloid tissue in a cell culture model to determine the effects of BTX-A incubation on cell proliferation and the expression of cytokines and growth factors such as IL-6, vascular endothelial growth factor, and TGF-β. They showed that none of the tested parameters of human keloid tissue were affected by BTX-A incubation and concluded that there was no evidence to suggest a significant therapeutic role for BTX-A injections in the treatment of keloids [70]. BTX-A also has analgesic properties that are not yet completely understood, but may disrupt the neuropathic painful symptoms that are present in some keloids [71].…”

Section: Methodsmentioning

confidence: 99%

Recent Developments in the Use of Intralesional Injections Keloid Treatment

et al. 2014

View full text Add to dashboard Cite

Keloid scars are often considered aesthetically unattractive and frustrating problems that occur following injuries. They cause functional and cosmetic deformities, displeasure, itching, pain, and psychological stress and possibly affect joint movement. The combination of these factors ultimately results in a compromised quality of life and diminished functional performance. Various methods have been implemented to improve keloid scars using both surgical and non-surgical approaches. However, it has proven to be a challenge to identify a universal treatment that can deliver optimal results for all types of scars. Through a PubMed search, we explored most of the literature that is available about the intralesional injection treatment of hypertrophic scars and keloids and highlights both current (corticosteroid, 5-fluorouracil, bleomycin, interferon, cryotherapy and verapamil) and future treatments (interleukin-10 and botulinum toxin type A). The reference lists of retrieved articles were also analysed. Information was gathered about the mechanism of each injection treatment, its benefits and associated adverse reactions, and possible strategies to address adverse reactions to provide reliable guidelines for determining the optimal treatment for particular types of keloid scars. This article will benefit practitioners by outlining evidence-based treatment strategies using intralesional injections for patients with hypertrophic scars and keloids.

show abstract

“…In one study BoNT/A had no effect on keloid fibroblast proliferation and cytokine expression (Haubner et al, 2014). However, other authors observed that BoNT/A alters the cell cycle and reduces proliferation of cultured fibroblasts isolated from hypertrophic scars (Zhibo and Miaobo, 2008).…”

Section: Effects On Cell Cycle and Apoptosismentioning

confidence: 98%